Provided by Tiger Trade Technology Pte. Ltd.

Atai Beckley Inc

7.38
-0.0400-0.54%
Post-market: 7.30-0.0800-1.08%19:59 EDT
Volume:4.31M
Turnover:31.97M
Market Cap:2.73B
PE:-3.46
High:7.45
Open:7.41
Low:7.38
Close:7.42
52wk High:7.45
52wk Low:3.27
Shares:369.95M
Float Shares:294.14M
Volume Ratio:0.51
T/O Rate:1.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1359
EPS(LYR):-2.9137
ROE:-417.21%
ROA:-39.03%
PB:15.48
PE(LYR):-2.53

Loading ...

Lilly to Acquire Ataibeckley to Advance Therapies for Treatment-resistant Depression and Other Mental Health Conditions

THOMSON REUTERS
·
Jul 16

Ataibeckley Surges After Report Says Lilly is Nearing Buyout Deal

Reuters
·
Jul 16

Premarkt Movers | ATAI Soars 42%; JBHT Jumps 8%; UAL Drops 2%; TSM Drops 3%; ASTS Drops 11%

Tiger Newspress
·
Jul 16

Ataibeckley Shares Jump 42.2% Premarket After Report Eli Lilly Nears Deal to Buy Co

THOMSON REUTERS
·
Jul 16

U.S. Research Roundup- Blackrock, Goldman Sachs, Synopsys

Reuters
·
Jul 16

AtaiBeckley (ATAI) Stock Skyrockets 65% After-Hours on Reported Eli Lilly Acquisition Talks

Benzinga_recent_news
·
Jul 16

24H | Ataibeckley Soars 56%. Eli Lilly Nears Deal to Buy Psychedelic Drugmaker Ataibeckley

Reuters
·
Jul 16

Major Pharma Giant Reportedly in Talks for Premium Acquisition of Psychedelics Firm

Stock News
·
Jul 16

Eli Lilly Nears Agreement to Acquire Psychedelic Drug Developer Atai Beckley

Deep News
·
Jul 16

AtaiBeckley jumps 55% after report of Eli Lilly takeover interest

TIPRANKS
·
Jul 16

Lilly Said to Near Deal for Psychedelic Drugmaker Ataibeckley- Bloomberg News

THOMSON REUTERS
·
Jul 16

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jul 15

Atai Beckley Director Robert Hershberg Disposes of Common Shares Worth $496,000

Reuters
·
Jul 10

ATAI Life Sciences is Maintained at Buy by Jefferies

Dow Jones
·
Jul 06

AtaiBeckley rumor highlighted in Betaville blog

TIPRANKS
·
Jul 06

AtaiBeckley Concludes Patient Dosing In Phase 2b Treatment-Resistant Depression Trial

MT Newswires Live
·
Jul 06

Atai Beckley Doses Last Patient in Vls-01 Phase 2b TRD Trial, Data Due Q4 2026

Reuters
·
Jul 06

Ataibeckley - Elumina Phase 2B Trial Randomized 156 Patients; Topline Data Expected Q4 2026

THOMSON REUTERS
·
Jul 06

Ataibeckley - Plans Phase 3 Vls-1 Trial in Major Depressive Disorder

THOMSON REUTERS
·
Jul 06

Did AtaiBeckley’s (ATAI) FTSE Russell Index Additions and BPL-003 Milestone Just Recast Its Investment Narrative?

Simply Wall St.
·
Jul 05